New Data Presented at ADA Demonstrate Early Effect of EndoBarrier Therapy on Glucose Control and Bil...
2015 Annual Meeting of Stockholders
Access for Participants by Webcast and Conference Call
GI Dynamics Announces Results of First Comparative Study of Gastric Bypass and EndoBarrier® Therapy...
The GI Dynamics’ EndoBarrier® Gastrointestinal Liner System is used for the treatment of obese type 2 diabetes with BMI ≥ 30 kg/m2, or obese patients with BMI ≥ 30 kg/m2 with ≥ 1 comorbidities, or obese patients with BMI >35 kg/m2.
The liner is indicated for maximum implant duration of 12 months.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE